ArticleCancer immunology, immunotherapy : CII2023

ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.

Karin Enell Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.